Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the Serious Outcomes Surveillance Network of the Canadian Immunization

S A McNeil ([email protected])1, M K Andrew1, L Ye1, F Haguinet2, T F Hatchette1, M ElSherif1, J LeBlanc1, A Ambrose1, A McGeer3, J E McElhaney4, M Loeb5, D MacKinnon-Cameron1, R Sharma6, G Dos Santos7, V Shinde8, on behalf of the Investigators of the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN)9 1. Canadian Center for Vaccinology, IWK Health Centre and Capital Health, Dalhousie University, Halifax, Nova Scotia, Canada 2. GlaxoSmithKline Vaccines, Wavre, Belgium 3. Mount Sinai Hospital, Toronto, Ontario, Canada 4. Advanced Medical Research Institute of Canada, Sudbury, Ontario, Canada 5. McMaster University, Hamilton, Ontario, Canada 6. GlaxoSmithKline Vaccines, Mississauga, Ontario, Canada 7. Business & Decision Life Sciences (on behalf of GlaxoSmithKline Vaccines), Brussels, Belgium 8. GlaxoSmithKline Vaccines, King of Prussia, Pennsylvania, United States 9. Investigators in the network (www.cirnetwork.ca) are listed at the end of the article